Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Inquiry Memorial
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation Report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
Support and FAQs
NHS Psychological Support
Support Groups
Infected Blood Support Schemes
Hepatitis C Testing
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
BPL noted that for the first year since Hepatitis B testing had first been carried out none of the five-litre plasma pools screened for Hepatitis B at regional transfusion centres and dispatched to the BPL had tested positive for Hepatitis B.
Published on:
30 August, 2024
Plasmapheresis grew as a source of plasma and, by 1986/1987, had given rise to just over 10% of the plasma sent to BPL.
Published on:
30 August, 2024
A new scheme of distribution for NHS Factor 8 concentrates was introduced. The amount to be sent to each region would be calculated by reference to the number of patients who had been reported as being treated in the haemophilia centres of that region in 1974.
Published on:
30 August, 2024
SAG-M was most likely introduced in September 1982.
Published on:
30 August, 2024
In Parliament, Dr Owen described the Government's policy as making the NHS self-sufficient in the production of Factor 8 as soon as "practicable".
Published on:
30 August, 2024
Elstree and Oxford were producing around 15 million international units of Factor 8 and NBTS was producing about the same amount in terms of cryoprecipitate.
Published on:
30 August, 2024
The additional donations required to meet self-sufficiency targets were calculated after detailed discussions between DHSS and regional transfusion centres. Some regions produced no fresh frozen plasma for factor concentrate at all, whereas Oxford and the North East Thames were producing large quantities.
Published on:
30 August, 2024
The Medicines Inspectorate began its inspection of BPL and concluded that planning for essential improvements should begin immediately and called for urgent action. It observed the current position was not a recent situation.
Published on:
30 August, 2024
Following the redevelopment of BPL, an increase in plasma supplies and factor concentrate production occurred.
Published on:
30 August, 2024
The Northern Regional Health Authority was offered increased capital and the West Midlands Regional Health Authority was offered an increased revenue allocation in order to produce the plasma required.
Published on:
30 August, 2024
In considering what needs the Department of Health should plan for, a review of blood and blood products in 1976 noted that there was little information to show whether current practices represented optimal use of products or whether figures were misleading due to wasteful practices.
Published on:
30 August, 2024
Thomas Dutton identified that the customary method of financing the NBTS was not conducive to the development of such a partnership and this was probably the biggest factor that led to the delay in mounting the AHG (Factor 8) concentrate production programme.
Published on:
30 August, 2024
The introduction of component therapy on a large scale reduced the need for independent, self-sufficient regional units.
Published on:
30 August, 2024
Thomas Dutton stated that devising and effectively managing a balanced programme for the preparation and distribution of blood components including clotting factors as "probably the most urgent task facing the NBTS" and he spoke of the need to fractionate something approaching one million donations annually.
Published on:
30 August, 2024
The 1975 target of 350,000 donor units was met, but Thomas Dutton stated that this target had long since been recognised as too low.
Published on:
30 August, 2024
Thomas Dutton observed that the Development of the NBTS Trends Report essentially said no more about Factor 8 requirements than some experts had been saying for years, which had now become generally accepted.
Published on:
30 August, 2024
Dr Waiter stated that it was accepted that in order to meet the anticipated demand for principal plasma fractions, a new plant in addition to that already available in the UK must be acquired.
Published on:
30 August, 2024
A pilot study conducted by Dr Robinson's team using the new Haemonetics v50 machine became a turning point in the UK, showing it enabled plasmapheresis more efficiently and more safely.
Published on:
30 August, 2024
No existing factory building could be found to accommodate BPL, even with adaptations.
Published on:
30 August, 2024
A lack of ministerial decision, ministerial uncertainty, and the absence of long-term management arrangements were issues identified by Mr Smart as hampering the work done by the Policy Steering Group for the re-development of BPL.
Published on:
30 August, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2088
Page
2089
Page
2090
Page
2091
Current page
2092
Page
2093
Page
2094
Page
2095
Page
2096
…
Next page
Next
Last page
Last